Watchlist

Watchlist
Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (ABUS)
Your Daily Pharma Scoop: Ablynx Takeover Bid, Celgene Acquires Impact Biomedicines, Axovant Flops Again
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss the hostile takeover bid from Novo Nordisk ( NVO ) for clinical-stage Belgian biotech company Ablynx ( OTCPK:ABLYF ). On Monday , Novo made a euro 2.6 billion ($3.1 billion) offer to acquire Ablynx. Novo has offered …
Premarket analyst action - healthcare
AmerisourceBergen (NYSE: ABC ) initiated with Outperform rating and $105 (12% upside) price target by Evercore ISI. More news on: AmerisourceBergen Corporation, Arbutus Biopharma Corp, AxoGen, Inc., Healthcare stocks news, Read more …
Going Out On A Limb: Expectations For Healthcare Stocks In January
In January 2016, the biopharmaceutical stocks declined sharply, and the relevant indices did not fully recover for nearly 18 months. In fact, the IBB now stands 5% below the level at which it closed out 2015. As I discussed in my 12/1/2017 article, we are on the verge of another great era in…
Risk-Adjusted Net Present Value For Arbutus Biopharma Corp
I wrote an article on July 19th to estimate the value of ABUS using a rNPV model. This new article is an update of the previous model to incorporate 3Q results. 2Q events were covered in this other article . You can see the first article here , where I explained the model in detail. Aln…
Nasdaq Biotech Index: 54 to be added, 15 removed
Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more …
Medical Stocks: Investing For 2018
2017 has turned out to be a good year for medical stocks, with strong gains in biopharmaceuticals, medical devices, diagnostics and HMOs. This can be attributed to a strong overall stock market, a quieting of concerns regarding drug pricing, an unchanged ACA and an underlying 6% growth rate …
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens US stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Ole Andreas Halvorsen&#x…
The Stock Market Cycle And Implications For Medical Stock Investing
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200…
Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview
The bioscience sector is poised with substantial growth and galvanized by promising prospects. One can earn 90% profits in one day, following a positive catalyst event. Stellar companies such as Kite Pharma (NASDAQ: KITE ), Amicus Therapeutics (NASDAQ: FOLD ), Conatus Pharmaceuticals (NASDAQ: …
Arbutus Biopharma's (ABUS) CEO Mark Murray on Q3 2017 Results - Earnings Call Transcript
Arbutus Biopharma Corp (ABUS) Q3 2017 Earnings Conference Call November 2, 2017 16:15 PM ET Executives Tiffany Tolmie - Manager, Investor Relations Mark Murray - Chief Executive Officer Bruce Cousins - Chief Financial Officer Mike Sofia - Chief Scientific Officer Bill Symonds…
Arbutus Biopharma beats by $0.20, beats on revenue
Arbutus Biopharma (NASDAQ: ABUS ): Q3 EPS of -$0.17 beats by $0.20 . More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, Read more …
Arbutus Biopharma Corporation (ABUS)